Dimerix (ASX:DXB)
We spoke with Dr Nina Webster, CEO of Dimerix (ASX: DXB), about the excellent economics behind DMX-200 for Focal Segmental Glomulerosclerosis (FSGS) and the near-term nature of the programme, with the first interim data from the current Phase 3 reading out shortly.
Check out the deep-dive research from Pitt Street Research here!
Also check our earlier interview with Dimerix here.
Check our ASX buy/sell tips
